Role of LDL in cardiovascular diseases: New datas and new recommendations;Rôle du LDL dans les maladies cardiovasculaires: Nouvelles données et nouvelles recommandations

Presse Medicale

Volumn 34, Issue 3, 2005, Pages 249-255

  Bruckert, E ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; RESIN; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE CONTROL; DRUG COST; DRUG EFFICACY; FEAR; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; MORBIDITY; MORTALITY; PATIENT CARE; PATIENT COMPLIANCE; REVIEW;

EID: 14644435849     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)88258-2     Document Type: Review

References (15)

1. Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J 1998; 19 Suppl A: A24-30.
2. Goldstein JL, Brown MS. Lipoprotein receptors and the control of plasma LDL cholesterol levels. Eur Heart J 1992; 13 Suppl B: 34-6.
3. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-6.
4. Warnick GR. Measurement of cholesterol and other lipoprotein constituents in the clinical laboratory. Clin Chem Lab Med 2000; 38: 287-300.
5. Voss R, Cullen P, Schulte H, Assmann G. Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Munster Study (PROCAM) using neural networks. Int J Epidemiol 2002; 31: 1253-62.
6. Li S, Chen W, Srinivasan SR, Bond MG, Tang R, Urbina EM, Berenson GS. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 2003; 290: 2271-6.
7. MRC/BHF Heart Protection study collaborative group. MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
8. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423.
9. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81.
10. Kastelein JJ. The future of best practice. Atherosclerosis 1999; 143 Suppl 1: S17-21.
11. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003; 290: 502-10.
12. Bruckert E, De Gennes JL, Malbecq W, Baigts F. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and mixed hyperlipidemia. Clin Cardiol 1995; 18: 621-9.
13. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy: the role of ézétimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 2003; 107: 3124-8.
14. Jones PH, Davidson MH, Stein EA, Bays HE, Mc Kenney JM, Miller E et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-60.
15. Bruckert E. New lipid-modifying therapies. Expert Opin Investig Drugs 2003; 12: 325-35.